Looking to fill a treatment gap, the U.S. Biomedical Advanced Research and Development Authority (BARDA) is launching the first stage of a $100 million prize competition to support development of broad-spectrum, small-molecule antiviral therapies targeting viruses in the Togaviridae and Flaviviridae families.
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Abbvie, Acadia, Astrazeneca, Daiichi Sankyo, Medtronic, Promega, Quanterix, Relay, Revealdx, Zeiss.
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Alto, Applied, Cycle, Eli Lilly, Hookipa, Illumina, Insilico, Menarini, Meiragtx, Neotrail, Newron, Owlet, Pacbio, Prophase, Setpoint, Stemline, WebAI, Zipbio, Zonsen.
Clinical updates for biopharma and med tech, including data readouts and publications: Alzheon, Avacta, Endospan, Inspira, NMD, Novo Nordisk, Olympus, Persica, Pfizer, Sagimet, Ultragenyx, Volta.
Biopharma and med-tech companies raising money in public or private financings, including: Adlai Nortye, Medx, Polaryx, Salspera, Sangamo, Sonovascular, Vaxcyte.
New hires and promotions in the biopharma and med-tech industries, including: Aptevo, B. Braun, Bicycle, Bioivt, CDR-Life, Hemostemix, Immorta, Kupando, Kyverna, Leonabio, Metabolon, Pyxis, Rigel, Spruce, Valo, Zelluna.
Despite reporting strong fourth-quarter (Q4) organic sales growth of $5.29 billion, up 12.7% year-on-year, Boston Scientific Corp. saw its shares plunge more than 17% in early trading. Investors appeared disappointed by weaker U.S. sales in the electrophysiology and Watchman businesses, two of the company’s growth engines, and concern over the 2026 organic growth guidance provided by management of 10% to 11%, down from the 15.8% seen in 2025.
Reauthorization of the rare pediatric disease priority review voucher (PRV) was included in the spending package signed into law Feb. 3 by U.S. President Donald Trump, removing at least one aspect of uncertainty facing rare disease companies, many of which have relied on the PRV’s transferrable option as a lucrative source of funding.
The U.K.’s main research funding agency is looking to put more public money into proof of concept and pre-seed funding of putative university spinouts, to make them more investible and improve relations between academics and investors. The move by UK Research and Innovation, which in 2026 will allocate £9.22 billion (US$12.58 billion) of taxpayer money across all fields of research, is in response to a government edict that the agency prioritizes outputs over inputs.
RSS
